Competition in the atopic dermatitis treatment market is intensifying again as new treatments have been made into health insurance benefits one after another. This is because salaries for severe atopic treatments have been expanded from April to children and adolescents. More fierce competition for market share is expected because the demand is high enough to insist on continuously expanding salaries in the clinical field. Experts say that Dupixent and Rinvoq, which directly benefited from the expansion of the salary range, have different characteristics, the choice of clinical sites will also depend on the patient's situation. According to the pharmaceutical industry on the 14th, competition among pharmaceutical com